Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol
| Autor: | Jia Hu, Savvas Nicolaou, Nicola Dalbeth, Maple Fung, Hyon K. Choi, Scott Baumgartner |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Allopurinol Immunology Urology Severe disease Severity of Illness Index General Biochemistry Genetics and Molecular Biology Gout Suppressants 03 medical and health sciences gout 0302 clinical medicine Rheumatology Monosodium urate Prevalence Humans Immunology and Allergy Medicine In patient Prospective Studies Aged 030203 arthritis & rheumatology treatment Arthritis Gouty business.industry Middle Aged Clinical and Epidemiological Research patient perspective medicine.disease United States Uric Acid Surgery Gout Serum urate 030104 developmental biology Crystal deposition Female Dual energy ct Tomography X-Ray Computed business New Zealand medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2017-212046 |
| Popis: | ObjectiveDual-energy CT (DECT) detects and quantifies monosodium urate (MSU) crystal deposition with high precision. This DECT study assessed crystal deposition in patients with gout treated with stable-dose allopurinol, and investigated potential clinical determinants for crystal deposition.MethodsPatients with gout treated with allopurinol ≥300 mg daily for at least 3 months were prospectively recruited from the USA and New Zealand, using monitored enrolment to include approximately 25% patients with palpable tophi and approximately 50% with serum urate (sUA) levels ResultsAmong 152 patients receiving allopurinol ≥300 mg/day for 5.1 years on average, 69.1% had crystal deposition on DECT, with a median total crystal volume of 0.16 cm3 (range: 0.01–19.53 cm3). The prevalence of crystal deposition ranged from 46.9% among patients with sUA ConclusionA substantial proportion of patients without palpable tophi have MSU crystal deposition, despite receiving allopurinol doses ≥300 mg/day for a considerable duration. Patients with higher sUA and clinical features of severe disease have a higher frequency and greater volume of MSU crystal deposition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|